Lise Byelyayeva
Lise Byelyayeva brings extensive experience in the development of therapies for hearing disorders through her work at Cilcare, a French–U.S.-based biotech company specialized in auditory science, where she has supported the development of drug and gene therapy programs for academic institutions, biotech startups, and pharmaceutical companies worldwide. With a background in neuroscience and strong business acumen, she bridges scientific and strategic domains to accelerate innovation in hearing therapeutics. Her focus on cross-sector collaboration, stakeholder engagement, and translational development enables her to drive impactful partnerships across the global hearing research ecosystem. Multilingual and internationally minded, Lise is committed to advancing solutions that improve outcomes for patients with hearing loss.
Company:Cilcare
Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. Cilcare External Innovation supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss, and tinnitus. Cilcare is based in Montpellier and Paris (France), and Lexington (near Boston), MA (USA).
